Clinical Trial: MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.

U.S., June 3 -- ClinicalTrials.gov registry received information related to the study (NCT07000292) titled 'MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.' on May 29.

Brief Summary: This study will evaluate the safety and efficacy of MSC303 in patients with Immune glomerular diseases.

Study Start Date: June 20

Study Type: INTERVENTIONAL

Condition: LN ANCA-GN

Intervention: DRUG: Injection of MSC303

Dose Group 1: D1, D8, D15, and D36 were respectively given 1, 5, 15, and 15 mg of MSC303 for injection; The second dose group: D1, D8, D15 and D36 were respectively given for injection MSC303 1, 5, 20, 20 mg.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Shanghai Changzheng Hospital

Information prov...